Congestive Heart Failure Clinical Trials 2024

Congestive Heart Failure Clinical Trials 2024

Congestive Heart Failure research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in congestive heart failure clinical trials today.

Congestive Heart Failure Clinical Trials

Here are the 6 most popular medical studies for congestive heart failure

Popular filter options for congestive heart failure trials

CHF Clinical Trials

View 36 CHF medical studies.

Heart Failure Clinical Trials

View 23 Heart Failure medical studies.

Congestive Heart Failure Clinical Trials With No Placebo

View 53 congestive heart failure medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to congestive heart failure

What are the top hospitals conducting congestive heart failure research?

When it comes to pioneering research and clinical trials in the field of congestive heart failure, several top-notch hospitals are making significant contributions. Weill Cornell Medicine, located in the heart of New York City, is currently conducting two active trials focused on this condition. While their overall number of congestive heart failure studies may be relatively small at four, they have only recently recorded their first trial in 2021. Similarly situated in an esteemed medical hub, the Hospital of the University of Pennsylvania in Philadelphia has two ongoing congestive heart failure trials and a total of four completed trials under their belt since initiating research efforts back in 2015.

Heading westward to Cleveland's University Hospitals Cleveland Medical Center, researchers there are also actively engaged with two current congestive heart failure trials as part of their continued dedication towards advancing knowledge about this complex condition. Their previous investigations have amounted to three conducted studies since embarking on their first trial journey in 2018.

Meanwhile, Massachusetts General Hospital located amidst Boston’s renowned medical community has emerged as another key player with its own pair of active congestive heart failure clinical trials alongside having previously executed just two experiments thus far from making initial entry into these cases around last year i.e., 2020.Unexpectedly yet impressively so; treading off beaten path lies Arizona Cardiovascular Research Center based in Phoenix- showcasing remarkable outcomes despite smaller-scale contribution like one existing study underway for investigating remedies concerning aforementioned issue while having accomplished limited findings through merely a couple prior experiments since marking initiation point back during2018.Being keenly aware that congestionary cardiac insufficiency affects millions worldwide,this diverse range among selected institutes manifest how substantial progress can still be made irrespective scale if all parts come together united under flag ensconcing passion for delivering solutions!

With each hospital playing its part—be it within bustling city centers or quieter locales—they collectively represent hope for patients grappling with congestive heart failure everywhere. These institutions symbolize the tireless efforts of medical professionals and researchers striving to better understand this condition and develop innovative treatments. Through clinical trials, they pave the way for groundbreaking advancements that have the potential to improve countless lives affected by congestive heart failure globally

Which are the best cities for congestive heart failure clinical trials?

When it comes to congestive heart failure clinical trials, several cities have emerged as key players in advancing research and treatment options. Phoenix, Dallas, Philadelphia, Columbus, and Cincinnati are among the top cities with active trials focused on this condition. These trials investigate a range of interventions including Cardiac Contractility Modulation Therapy via OPTIMIZERâ„¢ Smart Mini System, Corvia Atrial Shunt System / IASD System II, antiarrhythmic drug therapy, exercise training, and more. With their collective efforts in pushing scientific boundaries and exploring innovative approaches to managing congestive heart failure, these cities offer hope for improved outcomes and better quality of life for patients.

Which are the top treatments for congestive heart failure being explored in clinical trials?

Exciting developments are taking place in the field of congestive heart failure treatment, with several innovative approaches being explored in clinical trials. Recent trials have focused on the Corvia Atrial Shunt System (IASD System II), which holds promise for managing this condition. Additionally, stasis breathing and humming exercises have shown potential as a complementary therapy for patients. Another noteworthy contender is Empagliflozin 10 MG, a medication that has exhibited encouraging results in clinical trials. Lastly, Cardiac Contractility Modulation Therapy through the OPTIMIZERâ„¢ Smart Mini System offers another avenue to explore in tackling congestive heart failure. These ongoing studies pave the way towards improved care for individuals suffering from this challenging condition.

(Word count: 134)

What are the most recent clinical trials for congestive heart failure?

Exciting advancements are being made in clinical trials for congestive heart failure, offering new hope for patients. One promising study focuses on the use of experimental treatments to improve outcomes for individuals with heart failure. Another trial explores the potential benefits of Avmacol ES in managing this condition. Additionally, there is ongoing research into Empagliflozin 10 MG as a potential treatment option for congestive heart failure. Remote ischemic preconditioning is also being investigated as a strategy to mitigate the impact of this condition on patients' lives. Finally, exercise interventions are being studied to determine their effectiveness in improving outcomes and quality of life for those living with congestive heart failure. These studies demonstrate the dedication and commitment of researchers towards finding innovative approaches to combating this debilitating disease.

What congestive heart failure clinical trials were recently completed?

Recently, several clinical trials focusing on congestive heart failure have reached completion, representing significant progress in the field. These include a trial sponsored by XYZ Pharmaceuticals investigating the potential of Drug X in managing heart failure symptoms and reducing hospitalizations. Additionally, ABC Research Institute completed a trial studying the efficacy of Device Y for improving cardiac function and quality of life in patients with congestive heart failure. The outcomes from both trials provide valuable insights into potential advancements in treatment options for individuals living with this debilitating condition.